Outcome of patients with refractory/relapsed AML salvaged with the MEC (Mitoxantrone Etoposide Cytarabine) regimen.

被引：0

作者：

Castagnola, C ^{[1
]}

Alessandrino, EP ^{[1
]}

Pagnucco, G ^{[1
]}

Bernasconi, P ^{[1
]}

Lunghi, M ^{[1
]}

Colombo, A ^{[1
]}

Brusamolino, E ^{[1
]}

Bonfichi, M ^{[1
]}

Corso, A ^{[1
]}

Lazzarino, M ^{[1
]}

Bernasconi, C ^{[1
]}

机构：

[1] Univ Pavia, IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy

来源：

BLOOD | 2000年 / 96卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4627

引用

页码：210B / 210B

页数：1

共 50 条

[1] Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC)
Advani, R
Saba, H
Rowe, JM
Tallman, M
Wiernik, P
Ramek, J
Dugan, K
Litchman, M
Dorr, R
Lum, B
Sikic, B
Davis, E
Paietta, E
Greenberg, P
BLOOD, 1996, 88 (10) : 847 - 847
[2] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)
Advani, Anjali S.
Cooper, Brenda
Elson, Paul
Mukherjee, Sudipto
Fensterl, Jaime
Gerds, Aaron T.
Caimi, Paolo F.
Tomlinson, Ben K.
Malek, Ehsan
Little, Jane A.
Rush, Mary Lynn
Bogati, Samjhana
Parsons, Eric
Kane, Donna
Carraway, Hetty E.
Nazha, Aziz
Hamilton, Betty K.
Sobecks, Ronald
Bevier, Barbara
Goebel, Christopher
Zimmerman, Cassie
Nielsen, Alek D.
Hirsch, Cassandra M.
Maciejewski, Jaroslaw P.
Kalaycio, Matt
deLima, Marcos
Jacobberger, James
Woost, Philip
Sekeres, Mikkael A.
BLOOD, 2016, 128 (22)
[3] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia
Advani, Anjali
Elson, Paul
Hsi, Eric D.
Davis, Randall
Kalaycio, Matt
Sobecks, Ronald
Copelan, Edward
Duong, Hien K.
Foster, Bethany
Rush, Mary Lynn
Farhat, Leslie
Sekeres, Mikkael A.
BLOOD, 2012, 120 (21)
[4] MITOXANTRONE, ETOPOSIDE AND CYTARABINE (MEC) CAN INDUCE DEEP COMPLETE REMISSION AND IS AN EFFECTIVE BRIDGE THERAPY TO ALLOTRANSPLANTATION (SCT) IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA (AML) PATIENTS
Marconi, G.
Talami, A.
Abbenante, M. C.
Paolini, S.
Sartor, C.
Parisi, S.
De Polo, S.
Nanni, J.
Bertamini, L.
Ragaini, S.
Olivi, M.
Fontana, M. C.
Bochicchio, M. T.
Ottaviani, E.
Baldazzi, C.
Testoni, N.
Martinelli, G.
Cavo, M.
Papayannidisdegrees, C.
Curti, A.
HAEMATOLOGICA, 2019, 104 : 134 - 134
[5] Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allotransplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Marconi, Giovanni
Talami, Annalisa
Abbenante, Maria Chiara
Paolini, Stefania
Sartor, Chiara
Parisi, Sarah
de Polo, Stefano
Nanni, Jacopo
Bertamini, Luca
Ragaini, Simone
Olivi, Matteo
Fontana, Maria Chiara
Bochicchio, Maria Teresa
Ottaviani, Emanuela
Baldazzi, Carmen
Testoni, Nicoletta
Martinelli, Giovanni
Cavo, Michele
Papayannidis, Cristina
Curti, Antonio
BLOOD, 2018, 132
[6] A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Kuchroo, Manik Razdan
Redd, Robert A.
Garcia, Jacqueline S.
Keng, Michael
Hobbs, Gabriela S.
Rosenblatt, Jacalyn
Luskin, Marlise R.
Narayan, Rupa
Amrein, Philip C.
McMasters, Malgorzata
Wadleigh, Martha
Hock, Hanno
Stone, Richard
Neuberg, Donna S.
Avigan, David
Ballen, Karen K.
Fathi, Amir T.
DeAngelo, Daniel J.
Brunner, Andrew M.
BLOOD, 2023, 142
[7] Salvage chemotherapy with mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC) in refractory or relapsed acute leukemia in adults.
Jang, JH
Lee, ST
Hahn, JS
Ko, YW
Min, YH
BLOOD, 2001, 98 (11) : 213B - 213B
[8] APhase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
Advani, Anjali S.
Cooper, Brenda
Visconte, Valeria
Elson, Paul
Chan, Ricky
Carew, Jennifer
Wei, Wei
Mukherjee, Sudipto
Gerds, Aaron
Carraway, Hetty
Nazha, Aziz
Hamilton, Betty
Sobecks, Ronald
Caimi, Paolo
Tomlinson, Benjamin
Malek, Ehsan
Little, Jane
Miron, Alexander
Pink, John
Maciejewski, Jaroslaw
Unger, Allison
Kalaycio, Matt
de Lima, Marcos
Sekeres, Mikkael A.
CLINICAL CANCER RESEARCH, 2019, 25 (14) : 4231 - 4237
[9] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results
Advani, Anjali S.
Cooper, Brenda W.
Visconte, Valeria
Elson, Paul
Chan, E. Ricky
Carew, Jennifer
Mukherjee, Sudipto
Gerds, Aaron T.
Carraway, Hetty E.
Nazha, Aziz
Hamilton, Betty K.
Sobecks, Ronald
Caimi, Paolo
Tomlinson, Benjamin
Malek, Ehsan
Little, Jane A.
Fensterl, Jaime
Unger, Allison
Zimmerman, Cassie
Goebel, Christopher
Hoxha, Nita
Siebenaller, Caitlin
Thomas, Jenna
Rush, Mary Lynn
Bogati, Samjhana
Parsons, Eric
Diligente, Rachael
Kane, Donna
Nielsen, Alek
Hirsch, Cassandra M.
Edelheit, Simone
Miron, Alexander
Pink, John
Maciejewski, Jaroslaw P.
Kalaycio, Matt
De Lima, Marcos
Sekeres, Mikkael A.
BLOOD, 2017, 130
[10] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
Klisovic, Rebecca B.
Wang, Hongyan
Walker, Alison
Walsh, Katherine
Vasu, Sumithira
Garzon, Ramiro
Devine, Steven M.
Wang, Jiang
Garr, Celia
Norris, Adam
Byrd, John C.
Grever, Michael R.
Blum, William
Chan, Kenneth K.
Marcucci, Guido
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →